Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
Healthcare
$9.01 +4.29%
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
52W Low $5.68High $16.74
Volume 1.06M
Average 0.99M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$175.75M
FY 2025 · Annual
Investing Cash Flow
$179.99M
FY 2025 · Annual
Financing Cash Flow
$1.09M
FY 2025 · Annual
-99.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (67.49M) | 109.2M | (153.16M) | (167.58M) | (219.88M) |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| Deferred Income Tax | 3.1M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.38M | 27.96M | 30.44M | 37.82M | 36.04M |
| Change in Working Capital | (3.54M) | 11.18M | (339K) | (389K) | 14.08M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.84M) | (509K) | (167K) | (812K) | (839K) |
| Other Working Capital | 1.29M | 11.69M | (172K) | 423K | 14.92M |
| Other Non-Cash Items | 67K | (275.09M) | (11.52M) | (15.47M) | (6.31M) |
| Operating Cash Flow | (43.43M) | (126.66M) | (134.28M) | (145.3M) | (175.75M) |
| Capital Expenditures | (589.23K) | (1.13M) | (208K) | 0 | (49K) |
| Acquisitions (Net) | 923K | 275M | (36.01K) | 0 | 0 |
| Purchases of Investments | (525.81M) | (377.92M) | (373.38M) | (721.13M) | (236.53M) |
| Sales of Investments | 192.04M | 352.93M | 409.4M | 584.82M | 416.57M |
| Other Investing Activities | (333.78K) | 91K | 36.01K | 0 | 0 |
| Investing Cash Flow | (333.78M) | 248.98M | 35.81M | (136.31M) | 179.99M |
| Debt Repayment | 0 | (2.2M) | 1.83M | 0 | 0 |
| Common Stock Issued | 267.27M | 8.4M | 38.39M | 262.65M | 1.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | (32.13M) | 538K | 3.54M | 0 |
| Financing Cash Flow | 268.78M | (25.93M) | 40.75M | 266.19M | 1.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (108.42M) | 96.38M | (57.72M) | (15.43M) | 5.33M |
| Free Cash Flow | (44.02M) | (127.8M) | (134.48M) | (145.3M) | (175.8M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$219.9M
+ D&A$311.0K
+ Stock-Based Comp$36.0M
+ Deferred Tax$0
+ Working Capital$14.1M
- Other Non-Cash-$6.3M
= Operating Cash Flow-$175.8M
- Capex-$49.0K
= Free Cash Flow-$175.8M
Analysis
FY2025 free cash flow is -$175.8M. FCF conversion is 80.0% of net income. Operating cash flow was -$175.8M, with capex of -$49.0K. The largest bridge item is Stock-Based Comp at $36.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 |
Does CGEM generate free cash flow?
Cullinan Therapeutics, Inc. (CGEM) generated -$175.80M of free cash flow in fiscal 2025.
How much operating cash flow does CGEM produce?
Operating cash flow was -$175.75M, before capital expenditures of $49,000.00.
Continue the stock analysis
Jump to another research area for this company.